PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “GUANIDINE AND COMPOUNDS”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources
PubMed2003

[Total synthesis of marine cyclic guanidine compounds and development of novel guanidine type asymmetric organocatalysts].

Crambescidins and batzelladines, novel marine guanidine alkaloids, have unique pentacyclic and tricyclic guanidine core structures, respectively. They display a considerable array of biological activity and not surprisingly have attracted considerable synthetic interest. The first total synthesis of crambescidin 359 (7) and stereoselective total synthesis of batzelladine D (11) were accomplished based on a successive 1,3-dipolar cycloaddition reaction strategy. During synthetic studies of 7, the absolute stereochemistry was revealed. Based on the structure of 7, the novel C2-symmetric pentacyclic guanidine compounds 69a-d were designed and synthesized as guanidine organocatalysts. The catalyst 69b works efficiently as an asymmetric catalyst of the alkylation reaction of the glycynate-benzophenone Schiff base 73, which gives 74 with 80-90% ee.

Alkaloids↗
PubMed1982

Inhibition of plant and mammalian diamine oxidases by hydrazine and guanidine compounds.

1. Pig kidney and pea seedling diamine oxidases have similar sensitivity to methylhydrazine and phenylhydrazine as inhibitors. 2. Inhibition of pig kidney and pea seedling enzymes by hydrazine and guanidine compounds is time dependent. To reveal full inhibitory potency, methylhydrazine and aminoguanidine need longer preincubation with plant diamine oxidase as compared with mammalian diamine oxidase. 3. Impromidine, a known H2 histamine receptor agonist with guanidine and imidazole structures, and aminoguanidine have higher inhibitory activity towards pig kidney enzyme in comparison with the pea seedling one. 4. Impromidine inhibits pig kidney diamine oxidase in a noncompetitive manner. The Ki value is 6.6 muM. 5. The 24 hr dialysis of rat intestinal diamine oxidase preincubated with phenylhydrazine or impromidine only partially recovered the enzymic activities. 6. Impromidine inhibits mouse intestinal diamine oxidase in vivo.

Amine Oxidase (Copper-Containing)↗
PubMed1975

Cardiovascular activity of aromatic guanidine compounds.

A series of aromatic guanidines and several 1-phenylbiguanides was prepared and tested for cardiovascular (CV) effects in anesthetized dogs measuring heart rate, blood pressure, carotid artery blood flow, and myocardial force changes. The predominant CV effect at minimally effective dose was vasoconstriction unassociated with cardiac stimulation. The structure-activity relationships of the compounds were discussed comparing their structural similarities to the beta-phenylethylamines. The most potent members of the series were phenylguanidines substituted in the 3 and 4 positions on the aromatic nucleus with hydroxy or chloro groups. Preliminary mechanism studies indicated that the 3,4-dihydroxyphenylguanidines act at least partially by a direct alpha-adrenergic mechanism

Animals↗
PubMedDate not supplied

A new boron compound (guanidine biboric acid adduct) as an antitumour agent against Ehrlich ascites carcinoma in mice.

The inhibitory effects of a new boron compound of guanidine biboric acid adduct (GB) and guanidium chloride (L1) on the growth of ascites tumour in female Swiss mice were studied by monitoring the survival, tumour weight, tumour cell count, transplantability of Ehrlich ascites cells, precursor incorporation and the haematological parameters of the treated mice. 5-Fluorouracil, a known anticancer drug, was used as a positive control. The most important parameter was the survival time, which increased significantly when tumour-bearing mice were treated with the boron compound. Haematological parameters of the treated animals showed minimum toxic effects when boron was coupled with guanidine.

Animals↗
PubMed2003

EPR investigation of in vivo inhibitory effect of guanidine compounds on nitric oxide production in rat tissues.

The aim of the present study was to evaluate in vivo effects on NO production of pharmacologically widely used, commercially available NOS inhibitors, structurally related to guanidine. We compared the NO inhibitory potency and selectivity of L-NAME, aminoguanidine and guanabenz in tissues of normal and LPS-stimulated rats using ex vivo EPR measurements of the NO radical in its complex with dithiocarbamate-Fe(II). The tissues studied were the brain cortex, kidney, liver, heart and testis. Differential inhibitory effects were seen for L-NAME, aminoguanidine and guanabenz when applied during basal or LPS-stimulated conditions. Aminoguanidine exerted inhibition of NO only after stimulation with LPS. Guanabenz had little effect on NO in liver, kidney, testis and heart under normal conditions, while it reduced the basal NO in brain cortex. After stimulation with LPS guanabenz afforded a partial inhibition of the NO formation in all tissues studied. L-NAME was a potent inhibitor of NO synthesis in all tested tissues, both during basal and LPS stimulated conditions. Our results show that compounds containing a guanidine moiety might possess different NOS inhibitory profiles in vivo.

Animals↗
PubMed2006

A conformational study of phospha(III)- and phospha(V)-guanidine compounds.

Spectroscopic, crystallographic, and computational studies of the substituent distribution about the "NCN" unit in a series of phospha(III)- and phospha(V)-guanidines, R(2)PC{NR'}{NHR'} and R(2)P(E)C{NR'}{NHR'} (R = Ph, Cy; R' = (i)Pr, Cy; E = S, Se), are reported. In the phosphorus(III) systems, the P-diphenyl substituted compounds are observed as only one isomer, shown by NMR spectroscopy to be the E(syn)-(alpha) configuration. In contrast, the corresponding P-dicyclohexyl derivatives exist as a mixture of E(syn)-(alpha) and Z(anti) in solution. Spectroscopic techniques are unable to determine whether the latter isomer exists as the alpha- or beta-conformer relative to rotation about the P-C(amidine)() bond; however, DFT calculations indicate a low-energy structure for the N,N'-dimethyl model complex in the beta-conformation. In their oxidized sulfo and seleno forms, the P-diphenyl compounds are present as an interconverting equilibrium mixture of the E(syn)-(beta) and Z(syn)-(beta) isomers in solution ( approximately 3:2 ratio), whereas for the P-dicyclohexyl analogues, the latter configuration (in which the nitrogen substituents are in a more sterically unfavorably cisoid arrangement about the imine double bond) is the dominant form. Intramolecular E...HN (E = S, Se) interactions are observed in solution for the Z(syn)-(beta) configuration of both P-substituted species, characterized by J(SeH) coupling in the NMR spectrum for the P(V)-seleno compounds and a bathochromic shift of the NH absorption in the infrared spectrum. An X-ray crystallographic analysis of representative Ph(2)P(E)- and Cy(2)P(E)-substituted species shows exclusively the E(syn)-(beta) configuration for the P-diphenyl substituted compounds and the Z(syn)-(beta) form for the P-dicyclohexyl derivatives, independent of the chalcogen and the nitrogen substituents. Results from a DFT analysis of model compounds fail to identify a compelling electronic argument for the observed preferences in substituent orientation, suggesting that steric factors play an important role in determining the subtle energetic differences at work in these systems.

Journal Article↗